Focused On-demand Library for E3 ubiquitin-protein ligase synoviolin

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q86TM6

UPID:

SYVN1_HUMAN

Alternative names:

RING-type E3 ubiquitin transferase synoviolin; Synovial apoptosis inhibitor 1

Alternative UPACC:

Q86TM6; Q8N3K3; Q8N6E8; Q96JL5; Q96PK3

Background:

E3 ubiquitin-protein ligase synoviolin, also known as Synovial apoptosis inhibitor 1, plays a pivotal role in the endoplasmic reticulum quality control system. It specifically accepts ubiquitin from UBC7 E2 ligase, transferring it to substrates for degradation. This process is crucial for the disposal of misfolded proteins and the regulation of short-lived proteins. Additionally, it protects cells from ER stress-induced apoptosis and neurons from damage by promoting the degradation of harmful proteins.

Therapeutic significance:

Understanding the role of E3 ubiquitin-protein ligase synoviolin could open doors to potential therapeutic strategies. Its ability to mediate the degradation of misfolded proteins and protect cells from apoptosis highlights its potential as a target in diseases characterized by protein misfolding and cellular stress.